Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.86 USD
-0.20 (-0.44%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RARE 44.86 -0.20(-0.44%)
Will RARE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Ionis (IONS) Up 6% on Detailed Data From Angelman Drug Study
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Other News for RARE
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
Leerink upgrades Ionis to outperform, cites Angelman drug
Ultragenyx to present GTX-102 Angelman syndrome program update
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
Ultragenyx Pharmaceutical (RARE) Gets a Buy from Evercore ISI